Management of psoriasis patients with hepatitis B or hepatitis C virus infection

World Journal of Gastroenterology

Volumn 22, Issue 28, 2016, Pages 6444-6455

  Bonifati, Claudio ^a   Lora, Viviana ^a   Graceffa, Dario ^a   Nosotti, Lorenzo ^b  

^a SAN GALLICANO DERMATOLOGICAL INSTITUTE   (Italy)

^b ISTITUTO SUPERIORE DI SANITÀ   (Italy)

Author keywords

Biological disease modifying drugs; Conventional diseasemodifying drugs; Hepatitis B virus infection; Hepatitis C virus infection; Psoriasis; Therapy

Indexed keywords

ADALIMUMAB; ADEFOVIR; ALANINE AMINOTRANSFERASE; ALBUMIN; ALKALINE PHOSPHATASE; ANTIVIRUS AGENT; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; CERTOLIZUMAB PEGOL; CYCLOSPORIN; CYCLOSPORIN A; ENTECAVIR; ETANERCEPT; ETRETIN; GAMMA GLUTAMYLTRANSFERASE; GOLIMUMAB; HEPATITIS B CORE ANTIBODY; HEPATITIS B SURFACE ANTIBODY; HEPATITIS B SURFACE ANTIGEN; HEPATITIS C ANTIBODY; INFLIXIMAB; INTERFERON; LAMIVUDINE; METHOTREXATE; RIBAVIRIN; SECUKINUMAB; TENOFOVIR; USTEKINUMAB; VIRUS DNA; ANTIRHEUMATIC AGENT; DERMATOLOGICAL AGENT; HEPATITIS B ANTIBODY; IMMUNOSUPPRESSIVE AGENT;

ANTIBODY DETECTION; ARTICLE; COMORBIDITY; DISEASE COURSE; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HYPERTRIGLYCERIDEMIA; IMMUNOSUPPRESSIVE TREATMENT; INFECTION CONTROL; LIVER DISEASE; MUCOSAL DRYNESS; PATIENT MONITORING; PSORIASIS; RECOMMENDED DRUG DOSE; RISK ASSESSMENT; SCREENING TEST; TERATOGENICITY; THROMBOCYTE COUNT; TREATMENT DURATION; ULTRAVIOLET B RADIATION; VIRUS LOAD; VIRUS REACTIVATION; DISEASE MANAGEMENT; HEPATITIS B, CHRONIC; HEPATITIS C, CHRONIC; IMMUNOLOGY; MASS SCREENING; VIRUS ACTIVATION;

ANTIRHEUMATIC AGENTS; ANTIVIRAL AGENTS; COMORBIDITY; DERMATOLOGIC AGENTS; DISEASE MANAGEMENT; HEPATITIS B ANTIBODIES; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B, CHRONIC; HEPATITIS C ANTIBODIES; HEPATITIS C, CHRONIC; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MASS SCREENING; PSORIASIS; VIRUS ACTIVATION;

EID: 84979562091     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v22.i28.6444     Document Type: Article

References (112)

1. Christophers E. Psoriasis-epidemiology and clinical spectrum. Clin Exp Dermatol 2001; 26: 314-320 [PMID: 11422182 DOI: 10.1046/j.1365-2230.2001.00832.x]
2. Boehncke WH, Schön MP. Psoriasis. Lancet 2015; 386: 983-994 [PMID: 26025581 DOI: 10.1016/S0140-6736(14)61909-7]
3. Finlay AY. Current severe psoriasis and the rule of tens. Br J Dermatol 2005; 152: 861-867 [PMID: 15888138 DOI: 10.1111/j.1365-2133.2005.06502.x]
4. Mrowietz U, Kragballe K, Reich K, Spuls P, Griffiths CE, Nast A, Franke J, Antoniou C, Arenberger P, Balieva F, Bylaite M, Correia O, Daudén E, Gisondi P, Iversen L, Kemény L, Lahfa M, Nijsten T, Rantanen T, Reich A, Rosenbach T, Segaert S, Smith C, Talme T, Volc-Platzer B, Yawalkar N. Definition of treatment goals for moderate to severe psoriasis: a European consensus. Arch Dermatol Res 2011; 303: 1-10 [PMID: 20857129]
5. European Medicines Agency. Find medicine-Humira [Humira: EPAR-Product Information]. 2014. Available from: URL: http://www.ema.europa.eu/docs/en-GB/document-library/EPAR-Product-Information/human/000481/WC500050870.pdf
6. European Medicines Agency. Find medicine-Enbrel [Enbrel: EPAR-Product Information]. 2015. Available from: URL: http://www.ema.europa.eu/docs/en-GB/document-library/EPAR-Produ ct-Information/human/000262/WC500027361.pdf
7. European Medicines Agency. Find medicine-Remicade [Remicade: EPAR-Product Information]. 2014. Available from: URL: http://www.ema.europa.eu/docs/en-GB/document-library/EPAR-Product-Information/human/000240/WC500050888.pdf
8. European Medicines Agency. Find medicine-Stelara [Stelara: EPAR-Product Information]. 2014. Available from: URL: http://www.ema.europa.eu/docs/en-GB/document-library/EPAR-Product-Information/human/000958/WC500058513.pdf
9. Czarnecka-Operacz M, Sadowska-Przytocka A. The possibilities and principles of methotrexate treatment of psoriasis-the updated knowledge. Postepy Dermatol Alergol 2014; 31: 392-400 [PMID: 25610355 DOI: 10.5114/pdia.2014.47121]
10. Koutsianas C, Thomas K, Vassilopoulos D. Prevention of HBV reactivation in patients treated with biologic agents. Expert Rev Clin Pharmacol 2016; Epub ahead of print [PMID: 26775683 DOI: 10.1586/17512433.2016.1143773]
11. Booij MT, Van De Kerkhof PC. Acitretin revisited in the era of biologics. J Dermatolog Treat 2011; 22: 86-89 [PMID: 20673152 DOI: 10.3109/09546630903578582]
12. Hsu S, Papp KA, Lebwohl MG, Bagel J, Blauvelt A, Duffin KC, Crowley J, Eichenfield LF, Feldman SR, Fiorentino DF, Gelfand JM, Gottlieb AB, Jacobsen C, Kalb RE, Kavanaugh A, Korman NJ, Krueger GG, Michelon MA, Morison W, Ritchlin CT, Stein Gold L, Stone SP, Strober BE, Van Voorhees AS, Weiss SC, Wanat K, Bebo BF. Consensus guidelines for the management of plaque psoriasis. Arch Dermatol 2012; 148: 95-102 [PMID: 22250239 DOI: 10.1001/archdermatol.2011.1410]
13. Nast A, Boehncke WH, Mrowietz U, Ockenfels HM, Philipp S, Reich K, Rosenbach T, Sammain A, Schlaeger M, Sebastian M, Sterry W, Streit V, Augustin M, Erdmann R, Klaus J, Koza J, Muller S, Orzechowski HD, Rosumeck S, Schmid-Ott G, Weberschock T, Rzany B. S3-Guidelines on the treatment of psoriasis vulgaris (English version). Update. J Dtsch Dermatol Ges 2012; 10 Suppl 2: S1-95 [PMID: 22386073 DOI: 10.1111/j.1610-0387.2012.07919.x]
14. Smith CH, Anstey AV, Barker JN, Burden AD, Chalmers RJ, Chandler DA, Finlay AY, Griffiths CE, Jackson K, McHugh NJ, McKenna KE, Reynolds NJ, Ormerod AD. British Association of Dermatologists' guidelines for biologic interventions for psoriasis 2009. Br J Dermatol 2009; 161: 987-1019 [PMID: 19857207 DOI: 10.1111/j.1365-2133.2009.09505.x]
15. Motaparthi K, Stanisic V, Van Voorhees AS, Lebwohl MG, Hsu S. From the Medical Board of the National Psoriasis Foundation: Recommendations for screening for hepatitis B infection prior to initiating anti-tumor necrosis factor-alfa inhibitors or other immunosuppressive agents in patients with psoriasis. J Am Acad Dermatol 2014; 70: 178-186 [PMID: 24220724 DOI: 10.1016/j.jaad.2013.08.049]
16. Abramson A, Menter A, Perrillo R. Psoriasis, hepatitis B, and the tumor necrosis factor-alpha inhibitory agents: a review and recommendations for management. J Am Acad Dermatol 2012; 67: 1349-1361 [PMID: 22727462 DOI: 10.1016/j.jaad.2012.04.036]
17. Menter A, Gottlieb A, Feldman SR, Van Voorhees AS, Leonardi CL, Gordon KB, Lebwohl M, Koo JY, Elmets CA, Korman NJ, Beutner KR, Bhushan R. Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics. J Am Acad Dermatol 2008; 58: 826-850 [PMID: 18423260 DOI: 10.1016/j.jaad.2008.02.039]
18. Nast A, Gisondi P, Ormerod AD, Saiag P, Smith C, Spuls PI, Arenberger P, Bachelez H, Barker J, Dauden E, de Jong EM, Feist E, Jacobs A, Jobling R, Kemény L, Maccarone M, Mrowietz U, Papp KA, Paul C, Reich K, Rosumeck S, Talme T, Thio HB, van de Kerkhof P, Werner RN, Yawalkar N. European S3-Guidelines on the systemic treatment of psoriasis vulgaris-Update 2015-Short version-EDF in cooperation with EADV and IPC. J Eur Acad Dermatol Venereol 2015; 29: 2277-2294 [PMID: 26481193 DOI: 10.1111/jdv.13354]
19. Ahn CS, Dothard EH, Garner ML, Feldman SR, Huang WW. To test or not to test? An updated evidence-based assessment of the value of screening and monitoring tests when using systemic biologic agents to treat psoriasis and psoriatic arthritis. J Am Acad Dermatol 2015; 73: 420-428.e1 [PMID: 26184440 DOI: 10.1016/j.jaad.2015.06.004]
20. Bojito-Marrero L, Pyrsopoulos N. Hepatitis B and Hepatitis C Reactivation in the Biologic Era. J Clin Transl Hepatol 2014; 2: 240-246 [PMID: 26355300 DOI: 10.14218/JCTH.2014.00033]
21. Pérez-Alvarez R, Díaz-Lagares C, García-Hernández F, Lopez-Roses L, Brito-Zerón P, Pérez-de-Lis M, Retamozo S, Bové A, Bosch X, Sanchez-Tapias JM, Forns X, Ramos-Casals M. Hepatitis B virus (HBV) reactivation in patients receiving tumor necrosis factor (TNF)-targeted therapy: analysis of 257 cases. Medicine (Baltimore) 2011; 90: 359-371 [PMID: 22033451 DOI: 10.1097/MD.0b013e3182380a76]
22. WHO. Guidelines for the prevention, care and treatment of persons with chronic hepatitis B infection. Geneva Switzerland: World Health Organization, 2015
23. Terrault NA, Bzowej NH, Chang KM, Hwang JP, Jonas MM, Murad MH. AASLD guidelines for treatment of chronic hepatitis B. Hepatology 2016; 63: 261-283 [PMID: 26566064 DOI: 10.1002/hep.28156]
24. European Association For The Study Of The Liver. EASL clinical practice guidelines: Management of chronic hepatitis B virus infection. J Hepatol 2012; 57: 167-185 [PMID: 22436845 DOI: 10.1016/j.jhep.2012.02.010]
25. Marzano A, Angelucci E, Andreone P, Brunetto M, Bruno R, Burra P, Caraceni P, Daniele B, Di Marco V, Fabrizi F, Fagiuoli S, Grossi P, Lampertico P, Meliconi R, Mangia A, Puoti M, Raimondo G, Smedile A. Prophylaxis and treatment of hepatitis B in immunocompromised patients. Dig Liver Dis 2007; 39: 397-408 [PMID: 17382608 DOI: 10.1016/j.dld.2006.12.017]
26. López-Serrano P, Pérez-Calle JL, Sánchez-Tembleque MD. Hepatitis B and inflammatory bowel disease: role of antiviral prophylaxis. World J Gastroenterol 2013; 19: 1342-1348 [PMID: 23538480 DOI: 10.3748/wjg.v19.i9.1342]
27. López-Serrano P, de la Fuente Briongos E, Alonso EC, Pérez-Calle JL, Rodríguez CF. Hepatitis B and immunosuppressive therapies for chronic inflammatory diseases: When and how to apply prophylaxis, with a special focus on corticosteroid therapy. World J Hepatol 2015; 7: 539-547 [PMID: 25848477 DOI: 10.4254/wjh.v7.i3.539]
28. Hoofnagle JH. Reactivation of hepatitis B. Hepatology 2009; 49: S156-S165 [PMID: 19399803 DOI: 10.1002/hep.22945]
29. Cantini F, Boccia S, Goletti D, Iannone F, Leoncini E, Panic N, Prignano F, Gaeta GB. HBV Reactivation in Patients Treated with Antitumor Necrosis Factor-Alpha (TNF-?) Agents for Rheumatic and Dermatologic Conditions: A Systematic Review and Meta-Analysis. Int J Rheumatol 2014; 2014: 926836 [PMID: 25114684 DOI: 10.1155/2014/926836]
30. Ormerod AD, Campalani E, Goodfield MJ. British Association of Dermatologists guidelines on the efficacy and use of acitretin in dermatology. Br J Dermatol 2010; 162: 952-963 [PMID: 20423353 DOI: 10.1111/j.1365-2133.2010.09755.x]
31. Sandrini S, Callea F, Cristinelli L, Savoldi S, Setti G, Scaini P, Scolari F, Scalzini A, Pizzoccolo G, Maiorca R. Viral hepatitis in HBsAg-positive renal transplant patients treated with cyclosporin and steroids. Nephrol Dial Transplant 1990; 5: 525-530 [PMID: 2130300]
32. Dai MS, Kao WY, Shyu RY, Chao TY. Restoration of immunity and reactivation of hepatitis B virus after immunosuppressive therapy in a patient with severe aplastic anaemia. J Viral Hepat 2004; 11: 283-285 [PMID: 15117333 DOI: 10.1111/j.1365-2893.2004.00515. x]
33. Urata Y, Uesato R, Tanaka D, Kowatari K, Nitobe T, Nakamura Y, Motomura S. Prevalence of reactivation of hepatitis B virus replication in rheumatoid arthritis patients. Mod Rheumatol 2011; 21: 16-23 [PMID: 20668905 DOI: 10.1007/s10165-010-0337-z]
34. Oshima Y, Tsukamoto H, Tojo A. Association of hepatitis B with antirheumatic drugs: a case-control study. Mod Rheumatol 2013; 23: 694-704 [PMID: 22802011 DOI: 10.1007/s10165-012-0709-7]
35. Alfadhli AA, McDonald JW, Feagan BG. Methotrexate for induction of remission in refractory Crohn's disease. Cochrane Database Syst Rev 2005; (1): CD003459 [PMID: 15674908 DOI: 10.1002/14651858.CD003459.pub2]
36. Laohapand C, Arromdee E, Tanwandee T. Long-term use of methotrexate does not result in hepatitis B reactivation in rheumatologic patients. Hepatol Int 2015; 9: 202-208 [PMID: 25788188 DOI: 10.1007/s12072-014-9597-6]
37. Kalb RE, Strober B, Weinstein G, Lebwohl M. Methotrexate and psoriasis: 2009 National Psoriasis Foundation Consensus Conference. J Am Acad Dermatol 2009; 60: 824-837 [PMID: 19389524 DOI: 10.1016/j.jaad.2008.11.906]
38. Calabrese LH, Zein NN, Vassilopoulos D. Hepatitis B virus (HBV) reactivation with immunosuppressive therapy in rheumatic diseases: assessment and preventive strategies. Ann Rheum Dis 2006; 65: 983-989 [PMID: 16627542 DOI: 10.1136/ard.2005.043257]
39. Sansone S, Guarino M, Castiglione F, Rispo A, Auriemma F, Loperto I, Rea M, Caporaso N, Morisco F. Hepatitis B and C virus reactivation in immunosuppressed patients with inflammatory bowel disease. World J Gastroenterol 2014; 20: 3516-3524 [PMID: 24707134 DOI: 10.3748/wjg.v20.i13.3516]
40. Viganò M, Degasperi E, Aghemo A, Lampertico P, Colombo M. Anti-TNF drugs in patients with hepatitis B or C virus infection: safety and clinical management. Expert Opin Biol Ther 2012; 12: 193-207 [PMID: 22188392 DOI: 10.1517/14712598.2012.646986]
41. Lee YH, Bae SC, Song GG. Hepatitis B virus reactivation in HBsAg-positive patients with rheumatic diseases undergoing antitumor necrosis factor therapy or DMARDs. Int J Rheum Dis 2013; 16: 527-531 [PMID: 24164839 DOI: 10.1111/1756-185X.12154]
42. Charpin C, Guis S, Colson P, Borentain P, Mattéi JP, Alcaraz P, Balandraud N, Thomachot B, Roudier J, Gérolami R. Safety of TNF-blocking agents in rheumatic patients with serology suggesting past hepatitis B state: results from a cohort of 21 patients. Arthritis Res Ther 2009; 11: R179 [PMID: 19941642 DOI: 10.1186/ar2868]
43. Prestinari F, Ferguglia G, Laria G. Etanercept in a patient with severe psoriasis and latent viral hepatic disease and latent tuberculosis. Am J Clin Dermatol 2010; 11 Suppl 1: 57-58 [PMID: 20586514 DOI: 10.2165/1153429-S0-000000000-000000]
44. Nosotti L, Francesconi F, Izzi S, Berardesca E, Morrone A, Bonifati C. Safety of antitumour necrosis factor-? therapy in psoriatic patients with hepatitis B virus infection. Br J Dermatol 2010; 162: 1408-1410 [PMID: 20184582 DOI: 10.1111/j.1365-2133.2010.09714.x]
45. Caporali R, Bobbio-Pallavicini F, Atzeni F, Sakellariou G, Caprioli M, Montecucco C, Sarzi-Puttini P. Safety of tumor necrosis factor alpha blockers in hepatitis B virus occult carriers (hepatitis B surface antigen negative/anti-hepatitis B core antigen positive) with rheumatic diseases. Arthritis Care Res (Hoboken) 2010; 62: 749-754 [PMID: 20535784 DOI: 10.1002/acr.20130]
46. Kim YJ, Bae SC, Sung YK, Kim TH, Jun JB, Yoo DH, Kim TY, Sohn JH, Lee HS. Possible reactivation of potential hepatitis B virus occult infection by tumor necrosis factor-alpha blocker in the treatment of rheumatic diseases. J Rheumatol 2010; 37: 346-350 [PMID: 20008922 DOI: 10.3899/jrheum.090436]
47. Fotiadou C, Lazaridou E, Ioannides D. Safety of anti-tumour necrosis factor-? agents in psoriasis patients who were chronic hepatitis B carriers: a retrospective report of seven patients and brief review of the literature. J Eur Acad Dermatol Venereol 2011; 25: 471-474 [PMID: 20561122 DOI: 10.1111/j.1468-3083.2010.03754. x]
48. Prignano F, Ricceri F, Pescitelli L, Zanieri F, Lotti T. Tumour necrosis factor-? antagonists in patients with concurrent psoriasis and hepatitis B or hepatitis C: a retrospective analysis of 17 patients. Br J Dermatol 2011; 164: 645-647 [PMID: 21375517 DOI: 10.1111/j.1365-2133.2010.10140.x]
49. Cassano N, Mastrandrea V, Principi M, Loconsole F, De Tullio N, Di Leo A, Vena GA. Anti-tumor necrosis factor treatment in occult hepatitis B virus infection: a retrospective analysis of 62 patients with psoriatic disease. J Biol Regul Homeost Agents 2011; 25: 285-289 [PMID: 21880218]
50. Cho YT, Chen CH, Chiu HY, Tsai TF. Use of anti-tumor necrosis factor-? therapy in hepatitis B virus carriers with psoriasis or psoriatic arthritis: a case series in Taiwan. J Dermatol 2012; 39: 269-273 [PMID: 22077677 DOI: 10.1111/j.1346-8138.2011.01434. x]
51. Navarro R, Concha-Garzón MJ, Castaño C, Casal C, Guiu A, Daudén E. Outcome of patients with serology suggestive of past hepatitis B virus infection during antitumor necrosis factor therapy for psoriasis. Int J Dermatol 2014; 53: 909-911 [PMID: 24673290 DOI: 10.1111/ijd.12313]
52. Laurenti R, Giovannangeli F, Gubinelli E, Viviano MT, Errico A, Leoni L, Ballanti E, Migliore A. Long-term safety of anti-TNF adalimumab in HBc antibody-positive psoriatic arthritis patients: a retrospective case series of 8 patients. Clin Dev Immunol 2013; 2013: 410521 [PMID: 23606869 DOI: 10.1155/2013/410521]
53. Navarro R, Vilarrasa E, Herranz P, Puig L, Bordas X, Carrascosa JM, Taberner R, Ferrán M, García-Bustinduy M, Romero-Maté A, Pedragosa R, García-Diez A, Daudén E. Safety and effectiveness of ustekinumab and antitumour necrosis factor therapy in patients with psoriasis and chronic viral hepatitis B or C: a retrospective, multicentre study in a clinical setting. Br J Dermatol 2013; 168: 609-616 [PMID: 22985451 DOI: 10.1111/bjd.12045]
54. Sanz-Bueno J, Vanaclocha F, García-Doval I, Torrado R, Carretero G, Daudén E, Patricia Ruiz-Genao D, Alsina-Gibert MM, Pérez-Zafrilla B, Pérez-Rial G, Rivera R. Risk of Reactivation of Hepatitis B Virus Infection in Psoriasis Patients Treated With Biologics: A Retrospective Analysis of 20 Cases From the BIOBADADERM Database. Actas Dermosifiliogr 2015; 106: 477-482 [PMID: 25776200 DOI: 10.1016/j.ad.2015.01.010]
55. Giardina AR, Ferraro D, Ciccia F, Ferrante A, Di Stefano R, Craxì A, Triolo G. No detection of occult HBV-DNA in patients with various rheumatic diseases treated with anti-TNF agents: a twoyear prospective study. Clin Exp Rheumatol 2013; 31: 25-30 [PMID: 22935442]
56. Vassilopoulos D, Apostolopoulou A, Hadziyannis E, Papatheodoridis GV, Manolakopoulos S, Koskinas J, Manesis EK, Archimandritis AI. Long-term safety of anti-TNF treatment in patients with rheumatic diseases and chronic or resolved hepatitis B virus infection. Ann Rheum Dis 2010; 69: 1352-1355 [PMID: 20472596 DOI: 10.1136/ard.2009.127233]
57. Conde-Taboada A, Muñoz JP, Muñoz LC, López-Bran E. Infliximab treatment for severe psoriasis in a patient with active hepatitis B virus infection. J Am Acad Dermatol 2009; 60: 1077-1080 [PMID: 19467387 DOI: 10.1016/j.jaad.2008.09.057]
58. Schurich A, Pallett LJ, Lubowiecki M, Singh HD, Gill US, Kennedy PT, Nastouli E, Tanwar S, Rosenberg W, Maini MK. The third signal cytokine IL-12 rescues the anti-viral function of exhausted HBV-specific CD8 T cells. PLoS Pathog 2013; 9: e1003208 [PMID: 23516358 DOI: 10.1371/journal.ppat.1003208]
59. Zeuzem S, Carreño V. Interleukin-12 in the treatment of chronic hepatitis B and C. Antiviral Res 2001; 52: 181-188 [PMID: 11672828 DOI: 10.1016/S0166-3542(01)00183-8]
60. Chiu HY, Chen CH, Wu MS, Cheng YP, Tsai TF. The safety profile of ustekinumab in the treatment of patients with psoriasis and concurrent hepatitis B or C. Br J Dermatol 2013; 169: 1295-1303 [PMID: 23746170 DOI: 10.1111/bjd.12461]
61. Hayashi M, Umezawa Y, Fukuchi O, Ito T, Saeki H, Nakagawa H. Efficacy and safety of ustekinumab treatment in elderly patients with psoriasis. J Dermatol 2014; 41: 974-980 [PMID: 25346301 DOI: 10.1111/1346-8138.12653]
62. Koskinas J, Tampaki M, Doumba PP, Rallis E. Hepatitis B virus reactivation during therapy with ustekinumab for psoriasis in a hepatitis B surface-antigen-negative anti-HBs-positive patient. Br J Dermatol 2013; 168: 679-680 [PMID: 23121260 DOI: 10.1111/bjd.12120]
63. Steglich RB, Meneghello LP, Carvalho AV, Cheinquer H, Muller FM, Reginatto FP. The use of ustekinumab in a patient with severe psoriasis and positive HBV serology. An Bras Dermatol 2014; 89: 652-654 [PMID: 25054756 DOI: 10.1590/abd1806-4841.2014301]
64. Reddy KR, Beavers KL, Hammond SP, Lim JK, Falck-Ytter YT; American Gastroenterological Association Institute. American Gastroenterological Association Institute guideline on the prevention and treatment of hepatitis B virus reactivation during immunosuppressive drug therapy. Gastroenterology 2015; 148: 215-219; quiz 216-217 [PMID: 25447850]
65. Lee J, Conniff J, Kraus C, Schrager S. A Brief Clinical Update on Hepatitis C-The Essentials. WMJ 2015; 114: 263-269; quiz 270 [PMID: 26854315]
66. European Association for Study of Liver. EASL Recommendations on Treatment of Hepatitis C 2015. J Hepatol 2015; 63: 199-236 [PMID: 25911336 DOI: 10.1016/j.jhep.2015.03.025]
67. Frankel AJ, Van Voorhees AS, Hsu S, Korman NJ, Lebwohl MG, Bebo BF, Gottlieb AB. Treatment of psoriasis in patients with hepatitis C: from the Medical Board of the National Psoriasis Foundation. J Am Acad Dermatol 2009; 61: 1044-1055 [PMID: 19811848 DOI: 10.1016/j.jaad.2009.03.044]
68. Di Lernia V, Albertini G. Treatment of psoriasis with cyclosporine in patients with hepatitis C infection: risk or opportunity? J Am Acad Dermatol 2010; 63: 342-343 [PMID: 20633803 DOI: 10.1016/j.jaad.2009.11.593]
69. Miura H, Itoh Y, Matsumoto Y, Tani M, Tanabe N, Isonokami M, Kurachi K, Kozuka T. Long-term administration of cyclosporin A to HCV-antibody-positive patients with dermatologic diseases. Int J Dermatol 1999; 38: 310-314 [PMID: 10321952 DOI: 10.1046/j.1365-4362.1999.00690.x]
70. Galeazzi M, Bellisai F, Giannitti C, Manganelli S, Morozzi G, Sebastiani GD. Safety of cyclosporin A in HCV-infected patients: experience with cyclosporin A in patients affected by rheumatological disorders and concomitant HCV infection. Ann N Y Acad Sci 2007; 1110: 544-549 [PMID: 17911470 DOI: 10.1196/annals.1423.058]
71. Manna R, Verrecchia E, Fonnesu C, Giovinale M, De Socio G, Curigliano V, Cerquaglia C, Soriano A, Granata M, Migliore A, Massafra U, Gasbarrini G. Cyclosporine A: good response for patients affected by autoimmune disorders and HCV infection? Eur Rev Med Pharmacol Sci 2009; 13 Suppl 1: 63-69 [PMID: 19530514]
72. Giovanna Brunasso AM, Michetti P, Fancelli L, Massone C. Cyclosporine as monotherapy for psoriasis in the setting of chronic HCV infection: a forgotten therapeutical option. Hepat Mon 2012; 12: 349-352 [PMID: 22783348 DOI: 10.5812/hepatmon.6057]
73. Watashi K, Hijikata M, Hosaka M, Yamaji M, Shimotohno K. Cyclosporin A suppresses replication of hepatitis C virus genome in cultured hepatocytes. Hepatology 2003; 38: 1282-1288 [PMID: 14578868 DOI: 10.1053/jhep.2003.50449]
74. Imafuku S, Tashiro A, Furue M. Ciclosporin treatment of psoriasis in a patient with chronic hepatitis C. Br J Dermatol 2007; 156: 1367-1369 [PMID: 17441954 DOI: 10.1111/j.1365-2133.2007.07873.x]
75. Zylberberg H, Rimaniol AC, Pol S, Masson A, De Groote D, Berthelot P, Bach JF, Bréchot C, Zavala F. Soluble tumor necrosis factor receptors in chronic hepatitis C: a correlation with histological fibrosis and activity. J Hepatol 1999; 30: 185-191 [PMID: 10068094 DOI: 10.1016/S0168-8278(99)80060-800699]
76. Dill MT, Duong FH, Vogt JE, Bibert S, Bochud PY, Terracciano L, Papassotiropoulos A, Roth V, Heim MH. Interferon-induced gene expression is a stronger predictor of treatment response than IL28B genotype in patients with hepatitis C. Gastroenterology 2011; 140: 1021-1031 [PMID: 21111740 DOI: 10.1053/j.gastro.2010.11.039]
77. Nelson DR, Lim HL, Marousis CG, Fang JW, Davis GL, Shen L, Urdea MS, Kolberg JA, Lau JY. Activation of tumor necrosis factor-alpha system in chronic hepatitis C virus infection. Dig Dis Sci 1997; 42: 2487-2494 [PMID: 9440625]
78. Zein NN. Etanercept as an adjuvant to interferon and ribavirin in treatment-naive patients with chronic hepatitis C virus infection: a phase 2 randomized, double-blind, placebo-controlled study. J Hepatol 2005; 42: 315-322 [PMID: 15791697 DOI: 10.1023/A:1018804426724]
79. Pompili M, Biolato M, Miele L, Grieco A. Tumor necrosis factor-? inhibitors and chronic hepatitis C: a comprehensive literature review. World J Gastroenterol 2013; 19: 7867-7873 [PMID: 24307780 DOI: 10.3748/wjg.v19.i44.7867]
80. Khanna M, Shirodkar MA, Gottlieb AB. Etanercept therapy in patients with autoimmunity and hepatitis C. J Dermatolog Treat 2003; 14: 229-232 [PMID: 14660270 DOI: 10.1080/09546630310 020470]
81. Magliocco MA, Gottlieb AB. Etanercept therapy for patients with psoriatic arthritis and concurrent hepatitis C virus infection: report of 3 cases. J Am Acad Dermatol 2004; 51: 580-584 [PMID: 15389194 DOI: 10.1016/j.jaad.2004.05.013]
82. Cecchi R, Bartoli L. Psoriasis and hepatitis C treated with anti-TNF alpha therapy (etanercept). Dermatol Online J 2006; 12: 4 [PMID: 17459290]
83. De Simone C, Paradisi A, Capizzi R, Carbone A, Siciliano M, Amerio PL. Etanercept therapy in two patients with psoriasis and concomitant hepatitis C. J Am Acad Dermatol 2006; 54: 1102-1104 [PMID: 16713482 DOI: 10.1016/j.jaad.2005.11.1035]
84. Aslanidis S, Vassiliadis T, Pyrpasopoulou A, Douloumpakas I, Zamboulis C. Inhibition of TNFalpha does not induce viral reactivation in patients with chronic hepatitis C infection: two cases. Clin Rheumatol 2007; 26: 261-264 [PMID: 16924392 DOI: 10.1007/s10067-006-0394-z]
85. Rokhsar C, Rabhan N, Cohen SR. Etanercept monotherapy for a patient with psoriasis, psoriatic arthritis, and concomitant hepatitis C infection. J Am Acad Dermatol 2006; 54: 361-362 [PMID: 16443079 DOI: 10.1016/j.jaad.2005.05.043]
86. Pitarch G, Sanchez-Carazo JL, Mahiques L, Perez-Ferriols MA, Fortea JM. Treatment of psoriasis with adalimumab. Clin Exp Dermatol 2007; 32: 18-22 [PMID: 17305904 DOI: 10.1111/j.1365-2230.2006.02288.x]
87. Linardaki G, Katsarou O, Ioannidou P, Karafoulidou A, Boki K. Effective etanercept treatment for psoriatic arthritis complicating concomitant human immunodeficiency virus and hepatitis C virus infection. J Rheumatol 2007; 34: 1353-1355 [PMID: 17552060]
88. Alcaide AJ, Barrera MV, Habicheyn S, López N, Mendiola MV, Herrera E. Safety of etanercept therapy in a patient with psoriasis, Down's syndrome and concomitant hepatitis C virus infection. J Eur Acad Dermatol Venereol 2008; 22: 1514-1516 [PMID: 18355196 DOI: 10.1111/j.1468-3083.2008.02693.x]
89. Piccolo D, Di Cesare A, Fargnoli MC, Paoloni M, Vecchiotti S, Peris K. Effective control of psoriasis by etanercept in a patient with HCV-related diseases. Eur J Dermatol 2008; 18: 459-460 [PMID: 18573723 DOI: 10.1684/ejd.2008.0443]
90. Collazo MH, González JR, Torres EA. Etanercept therapy for psoriasis in a patient with concomitant hepatitis C and liver transplant. P R Health Sci J 2008; 27: 346-347 [PMID: 19069362]
91. Cassano N, Vena GA. Etanercept treatment in a hemodialysis patient with severe cyclosporine-resistant psoriasis and hepatitis C virus infection. Int J Dermatol 2008; 47: 980-981 [PMID: 18937672 DOI: 10.1111/j.1365-4632.2008.03619.x]
92. Cavazzana I, Ceribelli A, Cattaneo R, Franceschini F. Treatment with etanercept in six patients with chronic hepatitis C infection and systemic autoimmune diseases. Autoimmun Rev 2008; 8: 104-106 [PMID: 19014870 DOI: 10.1016/j.autrev.2008.05.002]
93. Behnam SE, Hindiyeh R, Fife DJ, Jeffes EW, Wu JJ. Etanercept as prophylactic psoriatic therapy before interferon-alpha and ribavirin treatment for active hepatitis C infection. Clin Exp Dermatol 2010; 35: 397-398 [PMID: 19663835 DOI: 10.1111/j.1365-2230.2009.03476.x]
94. Ventura F, Gomes J, Duarte Mda L, Fernandes JC, Brito C. Efficacy and safety of etanercept in patients with psoriasis and hepatitis C. Eur J Dermatol 2010; 20: 808-809 [PMID: 20923749 DOI: 10.1684/ejd.2010.1065]
95. Paradisi A, Caldarola G, Capizzi R, Siciliano M, Annichiarico E, Vecchio FM, Amerio PL, De Simone C. Safety of etanercept in patients with psoriasis and hepatitis C virus assessed by liver histopathology: preliminary data. J Am Acad Dermatol 2010; 62: 1067-1069 [PMID: 20466184 DOI: 10.1016/j.jaad.2009.07.010]
96. Prignano F, Zanieri F, Milani S, Lotti T. Switch from etanercept to efalizumab in a psoriatic patient with HCV infection: a case report. Dermatol Ther 2009; 22: 386-390 [PMID: 19580583 DOI: 10.1111/j.1529-8019.2009.01251.x]
97. Richetta AG, Maiani E, Carlomagno V, Carboni V, Mattozzi C, Giancristoforo S, Calvieri S. Treatment of erythrodermic psoriasis in HCV+ patient with adalimumab. Dermatol Ther 2009; 22 Suppl 1: S16-S18 [PMID: 19891686 DOI: 10.1111/j.1529-8019.2009.01266.x]
98. Garavaglia MC, Altomare G. Etanercept therapy in patients with psoriasis and concomitant HCV infection. Int J Immunopathol Pharmacol 2010; 23: 965-969 [PMID: 20943071]
99. Gandhi RK, Pickup T, Sheth PB. Is etanercept safe for treating plaque psoriasis in a patient with chronic hepatitis C virus infection? Arch Dermatol 2010; 146: 1151-1152 [PMID: 20956650 DOI: 10.1001/archdermatol.2010.253]
100. Di Lernia V, Guareschi E. Successful treatment of hand and foot psoriasis with infliximab. Dermatol Online J 2010; 16: 8 [PMID: 20673536]
101. Zanni M, Missale G, Santilli D, Di Nuzzo S. Etanercept in the treatment of psoriasis and psoriatic arthritis with concomitant hepatitis C virus infection: clinical and virological study in three patients. Eur J Dermatol 2011; 21: 564-567 [PMID: 21543290 DOI: 10.1684/ejd.2011.1318]
102. Mederacke I, Witte T, Wedemeyer H, Meyer-Olson D. Successful clearance of hepatitis C virus with pegylated interferon ?-2a and ribavirin in an etanercept-treated patient with psoriatic arthritis, hepatitis B virus coinfection and latent tuberculosis. Ann Rheum Dis 2011; 70: 1343-1344 [PMID: 21131645 DOI: 10.1136/ard.2010.139824]
103. Bartalesi F, Salomoni E, Cavallo A, Corti G, Pimpinelli N, Bartoloni A, Taliani G. Chronic hepatitis C virus hepatitis and psoriasis: no longer a contraindication to interferon use in the era of biological agents? Scand J Infect Dis 2013; 45: 320-323 [PMID: 23113733 DOI: 10.3109/00365548.2012.720026]
104. Costa L, Caso F, Atteno M, Giannitti C, Spadaro A, Ramonda R, Vezzù M, Del Puente A, Morisco F, Fiocco U, Galeazzi M, Punzi L, Scarpa R. Long-term safety of anti-TNF-? in PsA patients with concomitant HCV infection: a retrospective observational multicenter study on 15 patients. Clin Rheumatol 2014; 33: 273-276 [PMID: 23975363]
105. Di Nuzzo S, Boccaletti V, Fantini C, Cortelazzi C, Missale G, Fabrizi G, Lotti T, Hercogová J, Pagliarello C. Are Anti-TNF-? Agents Safe for Treating Psoriasis in Hepatitis C Virus Patients with Advanced Liver Disease? Case Reports and Review of the Literature. Dermatology 2016; 232: 102-106 [PMID: 26444967 DOI: 10.1159/000439587]
106. Salvi M, Macaluso L, Luci C, Mattozzi C, Paolino G, Aprea Y, Calvieri S, Richetta AG. Safety and efficacy of anti-tumor necrosis factors ? in patients with psoriasis and chronic hepatitis C. World J Clin Cases 2016; 4: 49-55 [PMID: 26881191 DOI: 10.12998/wjcc. v4.i2.49]
107. Cooper S, Erickson AL, Adams EJ, Kansopon J, Weiner AJ, Chien DY, Houghton M, Parham P, Walker CM. Analysis of a successful immune response against hepatitis C virus. Immunity 1999; 10: 439-449 [PMID: 10229187 DOI: 10.1016/S1074-7613(00)80044-8]
108. Lechner F, Wong DK, Dunbar PR, Chapman R, Chung RT, Dohrenwend P, Robbins G, Phillips R, Klenerman P, Walker BD. Analysis of successful immune responses in persons infected with hepatitis C virus. J Exp Med 2000; 191: 1499-1512 [PMID: 10790425]
109. Abuchar A, Vitiello M, Kerdel FA. Psoriasis treated with ustekinumab in a patient with hepatitis C. Int J Dermatol 2013; 52: 381-382 [PMID: 23414168 DOI: 10.1111/j.1365-4632.2011.04876. x]
110. Juan J, Feld JJ. Hepatitis B virus and hepatitis C virus treatment and management in patients receiving immune-modifying agents. Curr Opin Rheumatol 2014; 26: 395-403 [PMID: 24841230 DOI: 10.1097/BOR.0000000000000067]
111. Yang YW, Keller JJ, Lin HC. Medical comorbidity associated with psoriasis in adults: a population-based study. Br J Dermatol 2011; 165: 1037-1043 [PMID: 21711339 DOI: 10.1111/j.1365-2133.2011. 10494.x]
112. Cohen AD, Weitzman D, Birkenfeld S, Dreiher J. Psoriasis associated with hepatitis C but not with hepatitis B. Dermatology 2010; 220: 218-222 [PMID: 20185894 DOI: 10.1159/000286131]